Clifford Chance advises CVC on acquisition of Xi'an Yikang Pharmacy
6 March 2023
Clifford Chance advises CVC on acquisition of Xi'an Yikang Pharmacy
Leading international law firm Clifford Chance has advised global private equity firm CVC Capital Partners (CVC) on its buyout of Xi'an Yikang Pharmacy.
Clifford Chance previously advised CVC on its initial strategic investment in Yikang Pharmacy in 2021, and more recently on its acquisition of full control.
Yikang Pharmacy is a leading pharmaceutical retail chain business in Northwest China with more than 1,600 pharmacies and is a national leader among O2O (online to offline) and DTP (direct to patient) pharmacies. Through the investment, CVC will help Yikang Pharmacy to accelerate the growth of its business, implement standardised operating systems and continue to develop its digital health business.
China Co-Managing Partner Terence Foo commented, “We are immensely proud to support CVC, a longstanding client, on its investment in Yikang Pharmacy, as part of the continued interest from financial investors in expanding their portfolios in the healthcare industry in China as it evolves.”
Terence led the deal and was supported by consultant Julie Fu associate Cai Jiahong and trainee Rickey Yu. Partner Bai Yong and counsel Zibo Liu advised on the antitrust aspect. Clifford Chance acted as international counsel and Han Kun Law Offices acted as PRC counsel on this deal.
高伟绅就CVC Capital Partners收购西安怡康医药提供法律服务
国际领先律师事务所高伟绅为全球私募股权公司CVC Capital Partners(CVC)就其全面收购西安怡康医药(怡康医药)提供法律服务。
高伟绅曾在2021年就CVC对怡康医药的初始战略投资提供法律服务,近期就CVC全面收购怡康医药再次担任法律顾问。
怡康医药是中国西北地区领先的医药零售连锁企业,拥有1600多家药店,在O2O(线上到线下)和DTP(直接面向患者)药店中居于全国领先地位。通过此次投资,CVC将助力怡康医药加快业务增长,实施标准化的运营体系,并持续发展数字健康业务。
中国区联席管理合伙人符国成律师表示:我们非常荣幸能为CVC这一长期客户对怡康医药的投资提供法律服务,本交易展现了财务投资人在中国医疗保健行业发展过程中拓展投资组合的持续兴趣。
本交易由符国成律师领导,由富琪、蔡佳宏和余瑞麒提供支持。合伙人柏勇和刘子博在本交易中就反垄断事务提供法律服务。高伟绅在本交易中担任国际法律顾问,汉坤律师事务所在本交易中担任中国法律顾问。